| Policy / Commitment |
Continuously develop innovative products to meet customer needs and market expectations. |
| Short-Term Goals |
Achieve at least one new R&D project per year (combined across pharmaceutical, clinical, food, and cosmetic categories). |
| Medium- to Long-Term Goals |
1. Develop a new injectable formulation, SR-T100 Injection, proceed to human clinical trials, and apply for new drug registration upon completion of Phase III. |
| 2. Submit an Investigational New Drug (IND) application for SR-T100 Injection to the U.S. FDA. |
| 3. Restart the Phase II clinical trial in Taiwan for genital warts. |
| Resources Invested / Concrete Outcomes |
1. Pharmaceuticals: SR-T100 Injection (for malignant ascites in cancer patients) |
| ▲ Commissioned professional institutions to complete animal pharmacology and preclinical toxicology studies. |
| ▲ Completed 9 months of accelerated stability data; Phase I human clinical trial is scheduled to begin in Q3 2025. |
| ▲ Study results show efficacy in treating malignant ascites in cancer patients, with high safety and no chemotherapy-like side effects. |
| 2. SR-T100 Topical Gel (actinic keratosis & genital warts) |
| ▲ Completed Phase II clinical trials in Taiwan and the United States and obtained TFDA approval. |
| ▲ Plan to prioritize the Phase III trial for genital warts to move toward new drug market approval. |
| 3. Hepanamin® |
| ▲ Our PIC/S GMP pharmaceutical plant obtained TFDA certification in 2019 and 2020 for capsule and semi-solid dosage forms, respectively. |
| ▲ The drug license was approved in 2019 for in-house manufacturing, and mass production and sales have formally commenced. |
| ▲ Products have been exported to Singapore, Malaysia, and South Korea. |
| 4. Foods (Health Supplements) |
| ▲ “SR-100 Capsules” have been on the market for over 20 years, with sales continuing to grow. |
| ▲ Eye-care supplements are sold through major channels, and calcium and joint-support products were developed for launch in 2024. |
| 5. Skincare Products |
| ▲ “SR-100 Repair Gel” has been adopted by hospitals such as National Cheng Kung University Hospital and Tzu Chi Hospital, with clinical results published. |
| ▲ Developing specialized skincare products for dialysis patients, with a clinical trial involving 165 subjects scheduled to begin in 2025. |
